Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC decreased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 33.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 27,835 shares of the company's stock after selling 13,981 shares during the period. Hsbc Holdings PLC's holdings in Travere Therapeutics were worth $487,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of TVTX. Sterling Capital Management LLC lifted its position in shares of Travere Therapeutics by 859.8% in the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock valued at $41,000 after acquiring an additional 2,115 shares in the last quarter. R Squared Ltd purchased a new position in Travere Therapeutics in the 4th quarter worth approximately $53,000. Summit Investment Advisors Inc. boosted its stake in Travere Therapeutics by 9.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock worth $138,000 after purchasing an additional 667 shares during the period. Victory Capital Management Inc. purchased a new stake in Travere Therapeutics during the 4th quarter valued at approximately $182,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in shares of Travere Therapeutics during the fourth quarter valued at approximately $192,000.

Travere Therapeutics Trading Down 2.1 %

Shares of NASDAQ:TVTX traded down $0.42 during trading on Friday, reaching $20.02. 1,260,658 shares of the company were exchanged, compared to its average volume of 1,532,329. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The firm has a market capitalization of $1.78 billion, a PE ratio of -4.88 and a beta of 0.88. The business's fifty day simple moving average is $18.07 and its 200-day simple moving average is $18.82. Travere Therapeutics, Inc. has a 12-month low of $6.01 and a 12-month high of $25.29.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.08. The business had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business's revenue for the quarter was up 83.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.76) EPS. On average, research analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Insider Buying and Selling at Travere Therapeutics

In other news, insider Peter Heerma sold 3,074 shares of the business's stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $25.00, for a total transaction of $76,850.00. Following the sale, the insider now owns 127,634 shares in the company, valued at approximately $3,190,850. The trade was a 2.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Sandra Calvin sold 54,244 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the transaction, the chief accounting officer now directly owns 54,410 shares of the company's stock, valued at $1,360,250. The trade was a 49.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 96,420 shares of company stock valued at $2,302,575. Company insiders own 4.19% of the company's stock.

Wall Street Analyst Weigh In

TVTX has been the topic of a number of research reports. Citigroup lifted their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a report on Monday, February 24th. Evercore ISI raised their price target on Travere Therapeutics from $33.00 to $45.00 and gave the company an "outperform" rating in a report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a research note on Wednesday, April 23rd. JPMorgan Chase & Co. raised their target price on shares of Travere Therapeutics from $42.00 to $44.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Stifel Nicolaus boosted their price target on shares of Travere Therapeutics from $22.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.79.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.